Skip to main content
. Author manuscript; available in PMC: 2015 Dec 28.
Published in final edited form as: J Control Release. 2014 Oct 24;0:272–286. doi: 10.1016/j.jconrel.2014.10.016

Fig. 14.

Fig. 14

In vivo antitumor activity of various DOX formulations in PC-3 tumor-bearing mice. Solid arrows indicate the i.v. administration. A: relative tumor volume. B: body weight. *p < 0.001, compared to PEG5K-VE2/DOX or Doxil on day 31; & p < 0.01, compared to PEG5K-Fmoc-VE2/DOX (5 mg/kg) on day 31; # p < 0.01, compared to PEG5K-VE2/DOX or Doxil on day 31; € p < 0.001, compared to PEG5K-Fmoc-VE2/DOX (5 mg/kg) on day 40; α p < 0.05, compared to day 1.